What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2026-06-11 compared with 2025-12-11 · 47 added, 38 removed, 64 unchanged (57% of the section changed)

10 unchanged sentences

part of your investment.

There is economic

uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and

timing of the process of bringing our products to market through approvals with the FDA.

Our operating results

could be affected by the current political and economic uncertainties related to the economy of the United States, the domestic pharmaceutical

industry and world economies.

Future conditions may also adversely affect our pricing strategy, promotional activities and our profitability

The United States at the time of this filing is

involved with a war with Iran, the outcome of which could result in changes adverse to us in domestic and international markets, including

on tariffs and health care and medical products.

These changes could affect our promotional activities and our profitability and margins.

Additionally, many of the effects and consequences of U.S.

and global financial and economic conditions could potentially

have a material adverse effect on our liquidity and capital resources, including the ability to raise additional capital, if needed, or

could otherwise negatively affect our business and financial results.

Market instability could make it more difficult for us and our suppliers

to accurately forecast future product demand trends.

Additionally, inflationary factors such as increases in the costs to purchase products,

acquire product rights and overhead costs may adversely affect our operating results.

In this economic environment,

we are also subject to the risks common to low-revenue start-up enterprises, including, among other factors, undercapitalization, cash

shortages, limitations with respect to personnel, financial and other capital or operating expenditures.

Drug development companies typically

incur substantial losses during the product development and FDA testing phase of the business and do not generate revenues until after

the drug has received FDA approval, which cannot be assured, and until the company has started to sell the product.

We can give no assurance

that we can or will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our

early stage of operations.

and global financial and economic conditions and current stock market trends,

which are concentrating on companies in the artificial intelligence development market, could potentially have a material adverse effect

on our liquidity and capital resources, including the ability to raise additional capital, if needed, or could otherwise negatively affect

our business and financial results.

There is further economic uncertainty

concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing

of the process of bringing our products to market through approvals with the FDA.

Our operating results could be affected by the

current political and economic uncertainties related to the economy of the United States, the domestic pharmaceutical industry and world

Future conditions may also adversely affect our pricing strategy, promotional activities and our profitability and margins.

Additionally, many of the effects and consequences of U.S.

and global financial and economic conditions could potentially have a material

adverse effect on our liquidity and capital resources, including the ability to raise additional capital, if needed, or could otherwise

negatively affect our business and financial results.

Market instability could make it more difficult for us and our suppliers to accurately

forecast future product demand trends.

Additionally, inflationary factors such as increases in the costs to purchase products, acquire

product rights and overhead costs may adversely affect our operating results.

In this economic environment, we are also subject

to the risks common to low-revenue start-up enterprises, including, among other factors, undercapitalization, cash shortages, limitations

with respect to personnel, financial and other capital or operating expenditures.

Drug development companies typically incur substantial

losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug has received

FDA approval, which cannot be assured, and until the company has started to sell the product.

We can give no assurance that we can or

will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early stage of

We cannot assure you that we will be able to operate profitably or generate positive cash flow.

achieve profitability, we may be forced to cease operations and you may suffer a total loss of your investment.

If we cannot achieve profitability,

we may be forced to cease operations and you may suffer a total loss of your investment.

Because we do not have a product we can

26 unchanged sentences

our ability to attract and retain key personnel to manage our business effectively.

Our stock price has

been and is likely to continue to be volatile and you may not be able to resell shares of our common stock at or above the price you paid,

The trading price of

our common stock has experienced fluctuations due to the factors discussed in these risk factors.

In addition, the stock market in general

has, and the NASDAQ Capital Market and technology companies in particular have, experienced extreme price and volume fluctuations.

trading prices and valuations may not be sustainable.

These broad market and industry factors may decrease the market price of our common

stock, regardless of our actual operating performance.

In addition, in the past, following periods of volatility in the overall market

and the market price of a company’s securities, securities class action litigation has often been instituted against companies (primarily

those that are larger than us) that experienced such volatility.

This type of litigation, if instituted against us, regardless of its

outcome, could result in substantial costs and a diversion of our management’s attention and resources.

Our stock price has been and is likely to continue

to be volatile and you may not be able to resell shares of our common stock at or above the price you paid, if at all.

The trading price of our common stock has experienced

fluctuations due to the factors discussed in these risk factors.

In addition, the stock market in general has, and the NASDAQ Capital

Market and technology companies in particular have, experienced extreme price and volume fluctuations.

These trading prices and valuations

may not be sustainable.

These broad market and industry factors may decrease the market price of our common stock, regardless of our actual

operating performance.

In addition, in the past, following periods of volatility in the overall market and the market price of a company’s

securities, securities class action litigation has often been instituted against companies (primarily those that are larger than us) that

experienced such volatility.

This type of litigation, if instituted against us, regardless of its outcome, could result in substantial

costs and a diversion of our management’s attention and resources.

Stockholders may experience significant

22 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors